Hyperlactataemia in HIV‐infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)

摘要: Objective The aim of the study was to evaluate predictive value clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) RNA (mtRNA), for development lactic acidosis (LA) symptomatic hyperlactataemia (SHL). Methods In a substudy large multicentre, randomized trial three antiretroviral regimens, all containing didanosine (ddI) stavudine (d4T), in antiretroviral-naive, HIV-1-infected patients, patients with LA/SHL (‘cases’) were compared those without univariate analysis, significant parameters analysed multivariate model. In substudy, PBMC mtDNA mtRNA from cases matched controls at baseline time event examined. Results 911 subjects followed median 192 weeks, 24 identified (14 SHL 10 LA). more likely be female (P=0.05) have high body mass index (BMI) (P=0.02). analyses, only BMI remained an independent predictor (P=0.03). Between there no difference copy number (389 vs. 411 copies/cell, respectively; P=0.60) or (329 474 copies/cell, P=0.21), change (−65 +113 copies/cell, P=0.12), expression event, event. Conclusion The associated increased BMI, but did not predict LA/SHL. This demonstrates ineffectiveness routine measurement on ddI d4T as means predicting